{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:22:09Z","timestamp":1793697729496,"version":"4.5.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,13]]},"DOI":"10.7759\/cureus.84010","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:12:46Z","timestamp":1747116766000},"source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Atropine 0.05% Versus 0.01% for Prevention of Myopic Progression in Indian Children: A Randomized Clinical Trial"],"prefix":"10.7759","author":[{"given":"Siddharam S","family":"Janti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Mali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eereti","family":"Sahithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antarvedi","family":"Tejaswini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividya","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications","volume":"25","author":"Saw SM","year":"2005","unstructured":"Saw SM, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005, 25:381-91. 10.1111\/j.1475-1313.2005.00298.x","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(21)00135-7","article-title":"Association between digital smart device use and myopia: a systematic review and meta-analysis","volume":"3","author":"Foreman J","year":"2021","unstructured":"Foreman J, Salim AT, Praveen A, et al.. Association between digital smart device use and myopia: a systematic review and meta-analysis. Lancet Digit Health. 2021, 3:e806-18. 10.1016\/S2589-7500(21)00135-7","journal-title":"Lancet Digit Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140419","article-title":"The association between near work activities and myopia in children-a systematic review and meta-analysis","volume":"10","author":"Huang HM","year":"2015","unstructured":"Huang HM, Chang DS, Wu PC. The association between near work activities and myopia in children-a systematic review and meta-analysis. PLoS One. 2015, 10:e0140419. 10.1371\/journal.pone.0140419","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240750","article-title":"Prevalence of myopia in indian school children: meta-analysis of last four decades","volume":"15","author":"Agarwal D","year":"2020","unstructured":"Agarwal D, Saxena R, Gupta V, Mani K, Dhiman R, Bhardawaj A, Vashist P. Prevalence of myopia in indian school children: meta-analysis of last four decades. PLoS One. 2020, 15:e0240750. 10.1371\/journal.pone.0240750","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1227787","article-title":"Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis","volume":"14","author":"Hou P","year":"2023","unstructured":"Hou P, Wu D, Nie Y, Wei H, Liu L, Yang G. Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis. Front Pharmacol. 2023, 14:1227787. 10.3389\/fphar.2023.1227787","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman AE","year":"2020","unstructured":"Haarman AE, Enthoven CA, Tideman JW, Tedja MS, Verhoeven VJ, Klaver CC. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020, 61:49. 10.1167\/iovs.61.4.49","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.12.1760","article-title":"A randomized trial of the effects of rigid contact lenses on myopia progression","volume":"122","author":"Walline JJ","year":"2004","unstructured":"Walline JJ, Jones LA, Mutti DO, Zadnik K. A randomized trial of the effects of rigid contact lenses on myopia progression. Arch Ophthalmol. 2004, 122:1760-6. 10.1001\/archopht.122.12.1760","journal-title":"Arch Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cxo.12584","article-title":"Contact lenses to slow progression of myopia","volume":"100","author":"Sankaridurg P","year":"2017","unstructured":"Sankaridurg P. Contact lenses to slow progression of myopia. Clin Exp Optom. 2017, 100:432-7. 10.1111\/cxo.12584","journal-title":"Clin Exp Optom"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2)","volume":"119","author":"Chia A","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology. 2012, 119:347-54. 10.1016\/j.ophtha.2011.07.031","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.11.009","article-title":"Outdoor activity during class recess reduces myopia onset and progression in school children","volume":"120","author":"Wu PC","year":"2013","unstructured":"Wu PC, Tsai CL, Wu HL, Yang YH, Kuo HK. Outdoor activity during class recess reduces myopia onset and progression in school children. Ophthalmology. 2013, 120:1080-5. 10.1016\/j.ophtha.2012.11.009","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313739","article-title":"Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial","volume":"104","author":"Lam CS","year":"2020","unstructured":"Lam CS, Tang WC, Tse DY, et al.. Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020, 104:363-8. 10.1136\/bjophthalmol-2018-313739","journal-title":"Br J Ophthalmol"},{"key":"ref12","article-title":"Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation","volume":"15","author":"Barathi VA","year":"2009","unstructured":"Barathi VA, Weon SR, Beuerman RW. Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis. 2009, 15:1277-93.","journal-title":"Mol Vis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam JC","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, et al.. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019, 126:113-24. 10.1016\/j.ophtha.2018.05.029","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark TY","year":"2015","unstructured":"Clark TY, Clark RA. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. J Ocul Pharmacol Ther. 2015, 31:541-5. 10.1089\/jop.2015.0043","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2018.10.13","article-title":"The diluted atropine for inhibition of myopia progression in Korean children","volume":"11","author":"Moon JS","year":"2018","unstructured":"Moon JS, Shin SY. The diluted atropine for inhibition of myopia progression in Korean children. Int J Ophthalmol. 2018, 11:1657-62. 10.18240\/ijo.2018.10.13","journal-title":"Int J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in chinese children: a randomized clinical trial","volume":"138","author":"Wei S","year":"2020","unstructured":"Wei S, Li SM, An W, et al.. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in chinese children: a randomized clinical trial. JAMA Ophthalmol. 2020, 138:1178-84. 10.1001\/jamaophthalmol.2020.3820","journal-title":"JAMA Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial","volume":"141","author":"Zadnik K","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, et al.. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023, 141:990-9. 10.1001\/jamaophthalmol.2023.2097","journal-title":"JAMA Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01746-w","article-title":"Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis","volume":"20","author":"Zhao C","year":"2020","unstructured":"Zhao C, Cai C, Ding Q, Dai H. Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis. BMC Ophthalmol. 2020, 20:478. 10.1186\/s12886-020-01746-w","journal-title":"BMC Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25983","article-title":"Myopia - a 21st century public health issue","volume":"60","author":"Resnikoff S","year":"2019","unstructured":"Resnikoff S, Jonas JB, Friedman D, et al.. Myopia - a 21st century public health issue. Invest Ophthalmol Vis Sci. 2019, 60:Mi-Mii. 10.1167\/iovs.18-25983","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis","volume":"135","author":"Gong Q","year":"2017","unstructured":"Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L. Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. JAMA Ophthalmol. 2017, 135:624-30. 10.1001\/jamaophthalmol.2017.1091","journal-title":"JAMA Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1120672121998960","article-title":"Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute","volume":"31","author":"N\u00e9meth J","year":"2021","unstructured":"N\u00e9meth J, Tapaszt\u00f3 B, Aclimandos WA, et al.. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021, 31:853-83. 10.1177\/1120672121998960","journal-title":"Eur J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366728-safety-and-efficacy-of-atropine-005-versus-001-for-prevention-of-myopic-progression-in-indian-children-a-randomized-clinical-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:12:46Z","timestamp":1747116766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366728-safety-and-efficacy-of-atropine-005-versus-001-for-prevention-of-myopic-progression-in-indian-children-a-randomized-clinical-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.84010","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}